Study drug before surgery for ALK or ROS1 lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial tests WX-0593 given before surgery for certain types of lung cancer that have ALK or ROS1 gene changes. The goal is to shrink or control the cancer ahead of the operation and see how well the treatment works and is tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lung cancer that is confirmed under the microscope as non-small cell lung cancer (NSCLC).
- Your tumor test shows ALK-positive or ROS1-positive cancer, and it is Stage IB to Stage IIIA.
- Your surgical team believes the main tumor can be completely removed, using a team decision (including a thoracic cancer surgeon).
- Your activity level is good (ECOG 0 to 1), and you have at least one measurable tumor spot on scans.
- Your blood counts and organs (like liver and kidneys) are strong enough for study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a combination of three medicines before surgery can help shrink tumors in people with stage 2 or 3 non-small cell lung cancer, potentially making surgery and recovery more effective. The medicines include an immunotherapy drug (tislelizumab), a targeted therapy (anlotinib), and a chemotherapy drug (nab-paclitaxel).
This trial tests a targeted therapy pill (called iruplinalkib) given before surgery for people with a certain type of lung cancer (ALK-positive NSCLC). The goal is to see if the pill can shrink the tumor, making it easier to remove completely during surgery.
This trial tests giving targeted therapy pills before and after surgery for stage III lung cancer with certain rare gene changes. The goal is to see if this approach helps shrink or control the cancer better than surgery alone.
This trial tests whether taking lorlatinib before surgery can shrink or control early-stage lung cancer that has a specific genetic change (ALK). It aims to improve surgical outcomes and reduce the chance of the cancer coming back.
This study looks at whether giving a targeted therapy pill (lorlatinib) before surgery can help shrink ALK-positive lung cancer and improve outcomes. It also aims to understand why some tumors may not respond to this treatment.
This trial tests an investigational drug called JSKN016 given before surgery to shrink non-small cell lung cancer tumors and improve outcomes. The goal is to see if this pre-treatment is safe and effective for patients with stage II-III disease that can be surgically removed.
Hear when a new Non-Small Cell Lung Cancer(NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.